PCSK9 Inhibitors: Is There a Palatable Price Point?

Update: 2017-12-07

Description

The American Heart Association sessions featured two new analyses from the FOURIER trial, which prompted a discussion on the cost-effectiveness of PCSK9 inhibitor lipid-lowering therapy.

Comments

In Channel

New Diabetes Guidelines Already Outdated?

2018-04-1205:57

Empagliflozin Trims Liver Fat in Patients With T2D and NAFLD

2018-04-0902:51

Refer Medicare Patients for Free Diabetes Prevention Program

2018-03-2202:56

Which CGM for Which Diabetes Patient?

2018-02-1204:41

'Game Changer': Treat Diabetes and Also Reduce CV Risk

2018-02-0909:56

Vitamin and Mineral Supplements: Which Patients Will Benefit?

2018-02-0504:37

New Diabetes Guidelines Fail to Guide

2018-01-1906:14

Type 2 Diabetes in Kids: Don't Miss It

2018-01-1211:25

The Effects of Antihypertensive Meds on Microcirculation

2018-01-1001:28

What Cardiologists Need to Know About New Diabetes Drugs

2018-01-1012:09

Hormone Therapy and Chronic Conditions: Let's Get Rational

2018-01-0404:57

Testosterone Therapy and PCa Risk in Hypogonadal Men

2017-12-2704:23